1.79
1.79 (0%)
As of Apr 17, 2025
Entera Bio Ltd. [ENTX]
Source:
Company Overview
Entera is a clinical stage company focused on developing first-in-class oral tablet formats of peptides or protein replacement therapies. We focus on underserved, chronic medical conditions for which oral administration of a protein therapy has the potential to significantly shift a treatment paradigm.
| Country | Israel |
| Headquarters | jerusalem, israel |
| Phone Number | 972-2-532-7151 |
| Industry | manufacturing |
| CEO | Miranda Toledano |
| Website | enterabio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.2 |
| Operating Profit | $9.6 |
| Net Income | $9.5 |
| Net Cash | $-2.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | 5,295.6 |
| Profit as % of Revenues | 0.1% |
| Profit as % of Assets | 90.2% |
| Profit as % of Stockholder Equity | 118.1% |
Management Effectiveness
| Return on Equity | 118.1% |
| Return on Assets | 101.6% |
| Turnover Ratio | 1.7% |
| EBITA | $9.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $9.4 |
| Total Liabilities | $1.3 |
| Operating Cash Flow | $-6.8 |
| Investing Cash Flow | $-0 |
| Financing Cash Flow | $4.5 |
